Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

Background Early heart failure (HF) diagnosis is crucial to ensure that optimal guideline-directed medical therapy (GDMT) is administered to reduce morbidity and mortality. Limited access to ...

The following is a summary of “Impact of Exercise on Atrial Functional Mitral Regurgitation and Its Determinants: An Exercise ...

Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart failure is classified into two major clinical subtypes- heart failure with ...

Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...

Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart ...

led to an 18% reduction in cardiovascular death or worsening heart failure in patients with both mildly reduced and preserved ejection fraction, said AZ. Ejection fraction is a measure of how much ...

Researchers from the Nagoya University Graduate School of Medicine identified an enzyme, alpha-kinase 2 (ALPK2) that is specifically expressed in the heart. They found that the enzyme may prevent a ...

Danielle Rasooly, PhD, of the Division of Aging at Brigham and Women’s Hospital, is the co-corresponding author of a paper published in Nature Cardiovascular Research, “Large-scale multi-omics ...